MRK240913C113000
- 2.20
- 0.000.00%
Merck & Co Newsroom
Is the Federal Reserve starting an interest rate cut cycle on the cusp of a wave, possibly revealing the outcome of the election in advance?
Taking history as a lesson, in an election year with declining interest rates, the probability of the incumbent president or challenger winning is greater.
Investors Heavily Search Merck & Co., Inc. (MRK): Here Is What You Need to Know
BofA Securities Initiates Merck & Co(MRK.US) With Buy Rating, Announces Target Price $140
BofA Securities analyst Charlie CY Yang initiates coverage on $Merck & Co(MRK.US)$ with a buy rating, and sets the target price at $140.According to TipRanks data, the analyst has a success rate of 75
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Behind the Scenes of Merck & Co's Latest Options Trends
Over a hundred former Republican officials have written an open letter supporting Harris: Trump is not suitable to regain the White House.
① These Republican officials have served in institutions such as the White House, Department of Defense, Department of the Treasury, Department of State, Department of Justice, Department of Homeland Security, and Congress; ② These officials expressed that although there may be policy differences with Harris, compared to the "chaos and unethical behavior" displayed by Trump, these concerns are insignificant.
Roivant Flips a Skin Drug to Organon -- Barrons.com
Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript)
FDA Approves Merck's KEYTRUDA (Pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
Express News | FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
BioNTech Raised to Buy at Jefferies on New Cancer Drug
Merck's deruxtecan achieved the primary endpoint in a late-stage study of lung cancer.
According to Reuters on September 17th, Daiichi Sankyo and Merck announced on Tuesday that their jointly developed drug deruxtecan has achieved its primary endpoint in a late-stage study involving some lung cancer patients. Compared to patients receiving chemotherapy, deruxtecan can significantly prolong the lifespan of patients without cancer progression. This treatment is one of the three antibody-drug conjugates (ADCs) included in the $22 billion joint development and commercialization agreement signed by Merck and Daiichi Sankyo last year. Both companies plan to announce the trial data at an upcoming medical conference.
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Express News | Daiichi Sankyo Co Ltd - Safety Profile Consistent With Previous Trials, No New Safety Signals
Express News | Daiichi Sankyo Co Ltd - Phase 3 Trial Meets Primary Endpoint of Pfs
Express News | Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients With Locally Advanced or Metastatic Egfr-Mutated Non-Small Cell Lung Cancer in Herthena-Lung02 Phase 3 Trial
BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC
A Closer Look at 8 Analyst Recommendations For Merck & Co
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target